FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

The Food and Drug Administration (FDA) has approved the HIV preventing drug, lenacapavir, which only has to be administered twice a year. The injectable drug, sold as Yeztugo, can be taken by those at ...

Newly FDA-approved HIV prevention drug, Yeztugo, offers protection for six months—yet the need for a vaccine remains, say ...

Is the first and only FDA-approved HIV prevention option offering 6 months of protection, according to production company ...

The FDA has approved Gilead’s long-anticipated HIV prevention shot, Yeztugo, offering a twice-a-year alternative to daily ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Individuals at risk for sexually-acquired HIV have a new injectable option for preexposure prophylaxis with the US Food and Drug Administration’s (FDA’s) approval of lenacapavir, according to a press ...